RxDoctor Payments Data

Hamed Nayeb-Hashemi

Gastroenterology · Los Angeles, CANPI 1285874990

Payments from drug & device makers

$2,357in general payments, 2019–2025

Across 19 payments — averaging $124.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Redhill Biopharma Inc.$2K
  • AbbVie$145
  • Intercept Pharmaceuticals, Inc.$125
  • Novo Nordisk$121
  • Phathom Pharmaceuticals, Inc.$114
  • Boston Scientific$94
  • plus $257 from 7 others

What the payments were for

  • Speaking & faculty fees$1,50064%
  • Food & beverage$82635%
  • Education$301%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,357 in reported general payments places this provider in the 50th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California

Medicare billing

Part B allowed, 2024
$235,234
Medicare patients
749
Services billed
2,146

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab13$330,899
CreonLipase/Protease/Amylase52$93,578
LinzessLinaclotide93$82,583
MotegrityPrucalopride Succinate41$39,780
XifaxanRifaximin15$34,711
Mesalamine59$24,253
Dexlansoprazole DrDexlansoprazole65$19,454
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates256$16,321
Pantoprazole Sodium532$9,176
Ursodiol21$7,432
Balsalazide Disodium16$3,402
Lubiprostone13$2,991
Budesonide EcBudesonide11$2,528
Omeprazole190$2,348
Mercaptopurine24$1,983

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$145$176,161145 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,885 gastroenterology providers in California.

Other gastroenterology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →